📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein. (2022)

First Author: Owen DR

Attributed to: Pathfinder: An experimental medicine study of the 18 kD translocator protein as a novel neuroimmunodulatory target for multiple sclerosis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bcp.15392

PubMed Identifier: 35524344

Publication URI: http://europepmc.org/abstract/MED/35524344

Type: Journal Article/Review

Volume: 88

Parent Publication: British journal of clinical pharmacology

Issue: 9

ISSN: 0306-5251